MedTrace Logo

Brain Changes in Psoriasis After Secukinumab Treatment

NCT04717466 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.

Conditions

Interventions

BIOLOGICAL

Secukinumab

300mg subcutaneous injection

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Gil Yosipovitch, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2024-05-16
Completion
2025-03-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04717466 on ClinicalTrials.gov